The fact that the whole science base is still early stage and insecure is a fundamental problem for all who want to set up companies in this field. Some of the visionary proposals of 'therapeutic cloning', including the growth of replacement tissues from stem cells specifically generated for each patient, may not be masscompatible at all. All therapies which are derived from a patient's own cells will be difficult to assess in traditional clinical trials, as each treatment will be different, and may turn out to be extremely expensive.
Academic researchers at Oxford University led by Herman Waldmann and Paul Fairchild are developing a method to make cell therapies immunologically compatible to large numbers of patients, but they estimate that it could take more than a decade before such generally usable 'off the shelf' cell therapeutics might reach the clinic. So it may just be too early to raise great hopes for patients or investors in this field.
"The mixed fortunes of companies like Stem Cell Sciences may reflect the ambivalence of the general public towards stem cell biology: while the therapeutic benefits for the treatment of intractable diseases are evident to all, the journey to the clinic is far from straightforward, making it difficult to realise returns on investments in the short-term," says Fairchild.
Additionally, the wildly contradictory stem cell legislation across Europe and even between different states of the US implies that even if a company had a clinically proven stem cell therapy to sell today, they might find it very difficult to bring it to the market, or to arrange a deal with a major pharmaceutical company, who would want to avoid such difficulties.
Where does this leave the two British companies struggling for their funding? In spite of the very positive support of stem cell research by the UK government, the market introduction of Stem Cell Sciences has shown that investors are very cautious about such companies, due to all the scientific and political problems mentioned above. Maybe ReNeuron will need a bit more of Merlin's magic before things start happening. And in spite of all the legislative support for stem cell research in the UK and some other countries, moving research findings on towards a business might be more easily carried out elsewhere.
